Accor : Air France KLM’s announced eclipsed by interim results and guidance a shade below expectations
>Solid RevPAR trend should continue apace in H2 - Accor has reported solid H1 RevPARs, in line with our expectations at +5.1%, suggesting a slight slowdown in Q2 (North/Central/South America) despite still very solid momentum in all of the group’s main markets (France/Europe at +5.9% and Asia-Pacific at +4.8%). The prospects remain favourable for H2 (support of the tourism segment in France and a more favourable calendar in Germany, for example) despite a base effect ...Shenzhen Accord Pharmaceutical is engaged in the research, development and production of pharmaceuticals; and wholesales and chain retails of Chinese and western patent medicine, Chinese traditional medicine, biological products, bio-chemical medicine, health care products and medical apparatus and instruments. Through its subsidiaries, Co. is also engaged in the manufacture of raw material for chemical medicine, processing of Chinese patent drugs and medical chemical raw materials; sale of antibiotic preparations, chemical reagent and Chinese medical crop; and provision of logistic and storage services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.